• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作者与出版惯例。

Authors and publication practices.

作者信息

Farthing Michael J G

机构信息

St George's, University of London, London, SW17 0RE, United Kingdom.

出版信息

Sci Eng Ethics. 2006 Jan;12(1):41-52. doi: 10.1007/pl00022267.

DOI:10.1007/pl00022267
PMID:16501646
Abstract

Although authors are usually considered to be the main perpetrators of research and publication misconduct, any person involved in the process has the potential to offend. Editors may breach ethical standards particularly with respect to conflicts of interest. In the same way that authors are now required to declare competing interests, notably commercial affiliations, financial interests and personal connections, so must editors. Editors can influence the chances of acceptance or rejection of a paper by reviewer selection. Reviewers should also be ready to disclose conflicts of interest. They must ensure that their reviews are evidence based and free from destructive criticism driven by self interest. It seems likely that ultimately we will progressively move towards 'open' peer review in which both the authors and the reviewers are known to each other. There is an urgent need for increased transparency of the relationship between editors and owners. The events of the last few years indicate that unless this interface is fully understood by all parties, conflicts may arise. There is also a need for a radical overhaul in the relationship between journals, journal editors and the biomedical industry. It is now increasingly accepted that all clinical trials should be registered in a centrally held database and that protocols should include the primary and secondary outcome measures and the intended approach to data analysis thereby avoiding opportunistic post hoc analyses. However, the even more radical proposal that journals should cease to publish clinical trials sponsored by industry deserves wider debate.

摘要

尽管作者通常被视为研究和出版不当行为的主要肇事者,但参与该过程的任何人都有可能违规。编辑可能会违反道德标准,尤其是在利益冲突方面。与现在要求作者声明竞争利益(特别是商业附属关系、经济利益和个人关系)一样,编辑也必须这样做。编辑可以通过选择审稿人来影响论文被接受或拒绝的机会。审稿人也应该准备好披露利益冲突。他们必须确保自己的评审基于证据,且不受私利驱动的破坏性批评的影响。最终,我们似乎将逐步走向“开放”同行评审,即作者和审稿人相互知晓。迫切需要提高编辑与期刊所有者之间关系的透明度。过去几年的事件表明,除非各方都充分理解这种关系,否则可能会产生冲突。期刊、期刊编辑与生物医学行业之间的关系也需要彻底改革。现在越来越多人接受所有临床试验都应在一个集中的数据库中注册,并且方案应包括主要和次要结局指标以及数据分析的预期方法,从而避免机会主义的事后分析。然而,关于期刊应停止发表由行业赞助的临床试验这一更为激进的提议,值得进行更广泛的辩论。

相似文献

1
Authors and publication practices.作者与出版惯例。
Sci Eng Ethics. 2006 Jan;12(1):41-52. doi: 10.1007/pl00022267.
2
Ethical issues in biomedical publications.生物医学出版物中的伦理问题。
Hum Fertil (Camb). 2001;4(4):261-6. doi: 10.1080/1464727012000199631.
3
Nursing Journal Policies on Disclosure and Management of Conflicts of Interest.护理期刊利益冲突披露和管理政策。
J Nurs Scholarsh. 2020 Nov;52(6):680-687. doi: 10.1111/jnu.12605. Epub 2020 Oct 19.
4
Views of Iranian medical journal editors on medical research publication.伊朗医学期刊编辑对医学研究发表的看法。
Saudi Med J. 2004 Jan;25(1 Suppl):S29-33.
5
Responsible research publication: international standards for editors.负责任的研究发表:编辑的国际标准
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2014;35(3):35-41. doi: 10.1515/prilozi-2015-0006.
6
The ICMJE Recommendations and pharmaceutical marketing--strengths, weaknesses and the unsolved problem of attribution in publication ethics.国际医学期刊编辑委员会(ICMJE)建议与药品营销——出版伦理中的优势、劣势及未解决的归因问题
BMC Med Ethics. 2016 Apr 4;17:20. doi: 10.1186/s12910-016-0103-7.
7
Ethical issues in biomedical publications.生物医学出版物中的伦理问题。
Fertil Steril. 2002 May;77(5):883-8. doi: 10.1016/s0015-0282(02)03076-5.
8
Survey of conflict-of-interest disclosure policies of ophthalmology journals.眼科期刊利益冲突披露政策调查。
Ophthalmology. 2009 Jun;116(6):1093-6. doi: 10.1016/j.ophtha.2008.12.053. Epub 2009 Apr 19.
9
Editors Should Declare Conflicts of Interest.编辑应声明利益冲突。
J Bioeth Inq. 2019 Jun;16(2):279-298. doi: 10.1007/s11673-019-09908-2. Epub 2019 Apr 23.
10
Financial interest and its disclosure in scientific publications.科学出版物中的经济利益及其披露
JAMA. 1998 Jul 15;280(3):225-6. doi: 10.1001/jama.280.3.225.

引用本文的文献

1
Researcher views about funding sources and conflicts of interest in nanotechnology.研究人员对纳米技术的资金来源和利益冲突的看法。
Sci Eng Ethics. 2012 Dec;18(4):699-717. doi: 10.1007/s11948-011-9264-4. Epub 2011 Feb 19.
2
Conference summary: 'The responsible conduct of basic and clinical research'.会议总结:“基础与临床研究的负责任行为”
Sci Eng Ethics. 2006 Jan;12(1):189-97. doi: 10.1007/s11948-006-0019-6.

本文引用的文献

1
Medical journals are an extension of the marketing arm of pharmaceutical companies.医学期刊是制药公司营销部门的延伸。
PLoS Med. 2005 May;2(5):e138. doi: 10.1371/journal.pmed.0020138. Epub 2005 May 17.
2
Is this clinical trial fully registered?--A statement from the International Committee of Medical Journal Editors.该临床试验是否已完全注册?——来自国际医学期刊编辑委员会的声明。
N Engl J Med. 2005 Jun 9;352(23):2436-8. doi: 10.1056/NEJMe058127. Epub 2005 May 23.
3
Drug companies agree to make clinical trial results public.制药公司同意公布临床试验结果。
BMJ. 2005 Jan 15;330(7483):109. doi: 10.1136/bmj.330.7483.109.
4
GlaxoSmithKline to publish clinical trials after US lawsuit.葛兰素史克将在美国诉讼后公布临床试验结果。
BMJ. 2004 Jun 26;328(7455):1513. doi: 10.1136/bmj.328.7455.1513-a.
5
Improving peer review: who's responsible?改进同行评审:谁来负责?
BMJ. 2004 Mar 20;328(7441):657-8. doi: 10.1136/bmj.328.7441.657.
6
So inhaled steroids slow the rate of decline of FEV1 in patients with COPD after all?那么吸入性类固醇终究能减缓慢性阻塞性肺疾病(COPD)患者第一秒用力呼气容积(FEV1)的下降速率吗?
Thorax. 2003 Nov;58(11):911-3. doi: 10.1136/thorax.58.11.911.
7
Good publication practice for pharmaceutical companies.制药公司良好出版规范。
Curr Med Res Opin. 2003;19(3):149-54. doi: 10.1185/030079903125001767.
8
Editorial misconduct.编辑不当行为。
BMJ. 2003 Jun 7;326(7401):1224-5. doi: 10.1136/bmj.326.7401.1224.
9
Pharmaceutical industry sponsorship and research outcome and quality: systematic review.制药行业赞助与研究结果及质量:系统评价
BMJ. 2003 May 31;326(7400):1167-70. doi: 10.1136/bmj.326.7400.1167.
10
Journals under pressure: publish, and be damned.面临压力的期刊:发表文章,后果自负。
Nature. 2002 Oct 24;419(6909):772-6. doi: 10.1038/419772a.